CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 1
 

Inhibition of Prostaglandins May Be Mechanism by Which Aspirin Protects Against Certain Cancers

January 1, 1996

New research suggests that the reason aspirin(Drug information on aspirin) may protect against certain cancers is its ability to inhibit prostaglandins, chemicals naturally produced by the body that are suspected of playing a role in colorectal and lung cancer.

Prostaglandins are chemical messengers that send signals in the body, stimulating various activities, including blood clotting and neurotransmission. Prostaglandins are also immune suppressors, and their inhibition might improve the body's ability to fight cancer cells.

Scientists were led to study aspirin because anecdotal evidence has suggested that adults who take the drug on a regular basis for other maladies are less likely to die of colorectal cancer.

Now, preliminary research by Mack T. Ruffin IV, MD, of the University of Michigan Medical School, Ann Arbor, suggests that as little as 80 mg of acetylsalicylic acid (ASA), the dosage of a baby aspirin tablet, taken each day can lead to significant prostaglandin suppression. By comparison, a person with a headache might take two adult-strength tablets of approximately 325 mg ASA per tablet, as many as six times a day.

Speaking at the annual meeting of the American Association for Cancer Research (AACR), Dr. Ruffin described his study of 65 healthy adults given 14 days of a single daily dose of ASA or a placebo. The doses of ASA were 40, 80, 160, or 640 mg. Rectal tissue biopsies were taken to monitor changes in prostaglandin levels.

Dr. Ruffin said that 80 mg/day was the lowest effective dose and that prostaglandin production remained suppressed up to 3 days after the last dose. In addition, the research team observed that women produce significantly less prostaglandin than men. "Women also have a lower incidence of colorectal cancer," Dr. Ruffin said, suggesting a possible link.

Aspirin and Lung Cancer

In his AACR presentation, André Castonguay, PhD, of Laval University, Quebec City, Canada, reported on a study of the ability of various nonsteroidal anti-inflammatory drugs (NSAIDs) to suppress the development of lung cancer in mice given NNK, a powerful carcinogen found in cigarette smoke.

He found that mice who received unprocessed, nonformulated ASA had 60% fewer lung tumors, compared with the control group. In mice fed the aspirin form of ASA, tumors were reduced by 63%. Sulindac(Drug information on sulindac), an NSAID arthritis medication, suppressed tumor growth by 52%, he said, and buffered aspirin did not demonstrate any significant protection from tumors.

Avoid 'Cavalier' Use

Even though ASA is available over-the-counter, Dr. Ruffin warned that it should not be used in a cavalier manner, and should be considered an experimental cancer drug. ASA has many potential side effects, including stomach pain, bleeding ulcers, nausea, diarrhea, and vomiting.

As many as 4% of the population cannot tolerate normal doses of ASA because of side effects. In addition, some people are allergic to ASA, and the drug may interfere with other medications.

"It is ironic that in this era of high-tech medicine, researchers are taking a second look at this old standby," Dr. Ruffin said. "Scientists are rediscovering it, and may find that it has a potential impact beyond even what we speculate now."

Dr. Ruffin also stressed that ASA should not be used as a "magic bullet" to prevent cancer instead of following a healthy diet and lifestyle. Colorectal cancer is believed to be related to the high-fat, low-fiber North American diet, and he also suspects that there may be a relationship between prostaglandin levels and diet.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy